Study the effect of FGFR2 and FGFR4 gene variants on the response to cyclophosphamide doxorubicin-docetaxel based chemotherapy in locally advanced breast cancer patients | ||
| Egyptian Journal of Cancer and Biomedical Research | ||
| Volume 8, Issue 3, September 2024, Pages 19-32 PDF (1.32 M) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/jcbr.2024.294488.1357 | ||
| Authors | ||
| Omneya Ahmed Ibrahim Abdelkarem* 1; Amr Hussein2; Ayman Farouk3; Heba Elsheredy4; Mai Mamdouh Sayed abdel Aziz5; Sahar Mohamed Omer6 | ||
| 1Department of Chemical Pathology, Medical Research Institute, Alexandria University | ||
| 2Department of Clinical Oncology, Cancer Management and Research -Medical Research Institute – Alexandria University | ||
| 3Department of Experimental and Clinical Surgery – Medical Research Institute – Alexandria University | ||
| 4Assistant professor of clinical oncology. Department of Cancer Management and Research, Medical Research Institute, Alexandria University, Alexandria, Egypt | ||
| 5Department of Pathology- Medical Research Institute– Alexandria University | ||
| 6Department of of Chemical Pathology -Medical Research Institute – Alexandria University | ||
| Abstract | ||
| Background: Breast cancer has significantly increased in Arab populations, accounting for 13-30% of the newly diagnosed women malignancies. Neoadjuvant chemotherapy, including regimens based on cyclophosphamide, doxorubicin, and docetaxel, is effective for early-stage operable and locally advanced cancer.However, chemoresistance remains a major challenge. Therefore, we aimed to study FGFR2 (rs2981578) and FGFR4 (rs1966265) gene variants in predicting chemotherapy response in patients with locally advanced breast cancer. Methods: This cross-sectional study involved 30 females with biopsy confirmed locally advanced primary breast cancer. Patients received neoadjuvant anthracyclin-cyclophosphamide-docetaxel-based regimens. Core biopsies were taken for histopathological diagnosis, and immunohistochemistry for HER2, PR, and ER was performed. Genotyping of FGFR2 and FGFR4 SNPs was performed using the TaqMan SNP genotyping assay. The RECIST criteria was used for assessment of treatment response. Results: 66.7% of patients responded to chemotherapy, while 33.3% did not. Premenopausal patients showed a significantly higher response rate compared to menopausal patients (FEp=0.024). The distribution of FGFR2 and FGFR4 genotypes did not show significant difference between responders and non-responders. (FEp=1.000). Conclusion: The G and A alleles of FGFR2 and FGFR4 variants were not associated with chemotherapy response in this study. Further research with larger cohorts is needed to validate our study results and identify other variants that would guide tailored management. | ||
| Keywords | ||
| molecular markers; targeted therapy; gene variants; breast cancer; neoadjuvant chemotherapy | ||
|
Statistics Article View: 161 PDF Download: 213 |
||
